Introduction: To determine whether the addition of aspirin to a statin regimen is beneficial in reducing cardiovascular mortality, we analyzed data for uncomplicated hypertensive patients included in the Korea National Health Insurance sample cohort. Method: Among the 758433 eligible participants aged 20 years or older in 2005, 31115 participants were selected and divided into four groups: no-treatment group (N=19628); aspirin alone group (N=4814); statins alone group (N=4717); and combined treatment group (N=1956). The mean follow-up duration was 9413 months. The primary outcome of the study was all-cause and cardiovascular mortality from 2007 to 2013. Results: Treatment with aspirin alone [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.55-0.70; P<0.001), treatment with statins alone (HR, 0.48; 95% CI, 0.41-0.57; P<0.001), and combined treatment (HR, 0.43; 95% CI, 0.34-0.55; P<0.001) were independently associated with reductions in all-cause mortality. Treatment with aspirin alone (HR, 0.66; 95% CI, 0.53-0.84; P<0.001), treatment with statins alone (HR, 0.46; 95% CI, 0.33-0.64; P<0.001), and combined treatment (HR, 0.50; 95% CI, 0.31-0.79; P=0.003) were also independently associated with reductions in cardiovascular mortality. The addition of aspirin to statins was not associated with an additive benefit in reducing total mortality or cardiovascular mortality. Conclusion: Primary prevention with aspirin and/or statins is beneficial in reducing both all-cause and cardiovascular mortality in uncomplicated hypertensive participants. Nevertheless, as aspirin administration is associated with an increased risk of major bleeding, care must be taken to assess the risk/benefit of using aspirin in primary prevention.